838CD666-8E7E-417B-AA30-1197F9AE078D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.316688567674113
- age_years
- 41
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.571
- ADIPOGENESIS+0.483
- BILE_ACID_METABOLISM+0.462
- FATTY_ACID_METABOLISM+0.449
- COAGULATION+0.446
- XENOBIOTIC_METABOLISM+0.376
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.359
- PEROXISOME+0.356
- APOPTOSIS+0.313
- ANGIOGENESIS+0.302
Top 10 suppressed
- KRAS_SIGNALING_DN-0.245
- SPERMATOGENESIS-0.227
- HEDGEHOG_SIGNALING-0.207
- PANCREAS_BETA_CELLS-0.176
- G2M_CHECKPOINT-0.128
- E2F_TARGETS-0.100
- MYOGENESIS-0.069
- APICAL_JUNCTION-0.064
- UV_RESPONSE_DN-0.062
- APICAL_SURFACE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 034EEEB2-4BB6-4C72-A63A-C2012C43B4D7 | — | — | 0.897 |
| 2 | 62BFF895-C5CC-4F59-8348-2026B659FDF5 | — | — | 0.877 |
| 3 | 7C6AF8DD-EFA4-4AD7-8AAC-918D686D78BA | — | — | 0.867 |
| 4 | SRR15030876 | — | — | 0.852 |
| 5 | 5B9DEC62-3DC7-4DE2-8B20-3E191594FCB4 | — | — | 0.849 |
| 6 | D2201D51-9020-4A0D-B2C8-8F7A2F0A918A | — | — | 0.846 |
| 7 | MNG228 | — | — | 0.844 |
| 8 | BS_AGTPCRR4 | Posterior Fossa Ependymoma | — | 0.842 |
| 9 | 6F4F72B3-E2B1-48DD-B9F4-C03AFCE79566 | — | — | 0.832 |
| 10 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.571 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.483 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.462 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.449 | Inavolisib | — uncovered |
| COAGULATION | 0.446 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.376 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.359 | Inavolisib | — uncovered |
| PEROXISOME | 0.356 | Idelalisib | — uncovered |
| APOPTOSIS | 0.313 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.302 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.266 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.249 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.246 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.235 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.234 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.234 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.231 | Inavolisib | — uncovered |
| COMPLEMENT | 0.223 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |